Beta-synuclein: Difference between revisions
m (Robot: Automated text replacement (-{{WikiDoc Cardiology Network Infobox}} +, -<references /> +{{reflist|2}}, -{{reflist}} +{{reflist|2}})) |
m (Bot: HTTP→HTTPS) |
||
Line 1: | Line 1: | ||
{{Infobox_gene}} | |||
{{ | '''Beta-synuclein''' is a [[protein]] that in humans is encoded by the ''SNCB'' [[gene]].<ref name="pmid7558013">{{cite journal | vauthors = Spillantini MG, Divane A, Goedert M | title = Assignment of human alpha-synuclein (SNCA) and beta-synuclein (SNCB) genes to chromosomes 4q21 and 5q35 | journal = Genomics | volume = 27 | issue = 2 | pages = 379–81 |date=Nov 1995 | pmid = 7558013 | pmc = | doi = 10.1006/geno.1995.1063 }}</ref><ref name="pmid9806846">{{cite journal | vauthors = Lavedan C, Leroy E, Torres R, Dehejia A, Dutra A, Buchholtz S, Nussbaum RL, Polymeropoulos MH | title = Genomic organization and expression of the human beta-synuclein gene (SNCB) | journal = Genomics | volume = 54 | issue = 1 | pages = 173–5 |date=Jan 1999 | pmid = 9806846 | pmc = | doi = 10.1006/geno.1998.5556 }}</ref><ref name="entrez">{{cite web | title = Entrez Gene: SNCB synuclein, beta| url = https://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=6620| accessdate = }}</ref> | ||
}} | |||
{{ | |||
| | |||
<!-- The PBB_Summary template is automatically maintained by Protein Box Bot. See Template:PBB_Controls to Stop updates. --> | <!-- The PBB_Summary template is automatically maintained by Protein Box Bot. See Template:PBB_Controls to Stop updates. --> | ||
{{PBB_Summary | {{PBB_Summary | ||
| section_title = | | section_title = | ||
| summary_text = The protein encoded by this gene is highly homologous to alpha-synuclein. These proteins are abundantly expressed in the brain and putatively inhibit phospholipase D2 selectively. The encoded protein, which may play a role in neuronal plasticity, is abundant in neurofibrillary lesions of patients with Alzheimer disease. This protein has been shown to be highly expressed in the substantia nigra of the brain, a region of neuronal degeneration in patients with Parkinson disease; however, no direct relation to Parkinson disease has been established. Two transcript variants encoding the same protein have been found for this gene.<ref name="entrez" | | summary_text = The [[protein]] encoded by this gene is highly [[Homology (biology)|homologous]] to [[alpha-synuclein]]. These proteins are abundantly expressed in the brain and putatively inhibit [[phospholipase]] D2 selectively. The encoded protein, which may play a role in neuronal plasticity, is abundant in neurofibrillary lesions of patients with [[Alzheimer's disease]]. This protein has been shown to be highly expressed in the substantia nigra of the brain, a region of neuronal degeneration in patients with [[Parkinson's disease]]; however, no direct relation to Parkinson's disease has been established. Two transcript variants encoding the same protein have been found for this gene.<ref name="entrez"/> | ||
}} | }} | ||
Beta-synuclein is a [[synuclein]] [[protein]] found primarily in [[neural tissue|brain tissue]] and is seen mainly in [[presynaptic]] terminals. Beta-synuclein is predominantly expressed in the [[neocortex]], [[hippocampus]], [[striatum]], [[thalamus]], and [[cerebellum]]. It is not found in [[Lewy body|Lewy bodies]], but it is associated with hippocampal pathology in [[Parkinson's disease]] and [[dementia with Lewy bodies]].<ref>George | Beta-synuclein is a [[synuclein]] [[protein]] found primarily in [[neural tissue|brain tissue]] and is seen mainly in [[presynaptic]] terminals. Beta-synuclein is predominantly expressed in the [[neocortex]], [[hippocampus]], [[striatum]], [[thalamus]], and [[cerebellum]]. It is not found in [[Lewy body|Lewy bodies]], but it is associated with hippocampal pathology in [[Parkinson's disease|PD]] and [[dementia with Lewy bodies|DLB]].<ref>{{cite journal | last1 = George | first1 = JM | title = The synucleins | journal = Genome Biology | volume = 3 | issue = 1 | pages = REVIEWS3002 | year = 2002 | pmid = 11806835 | pmc = 150459 | doi=10.1186/gb-2001-3-1-reviews3002}}</ref> | ||
Beta-synuclein is suggested to be an inhibitor of [[alpha-synuclein]] aggregation, which occurs in [[neurodegenerative disease]]s such as [[Parkinson's disease]]. Thus, beta-synuclein may protect the [[central nervous system]] from the [[neurotoxicity|neurotoxic]] effects of alpha-synuclein and provide a novel treatment of neurodegenerative disorders.<ref>Hashimoto M | Beta-synuclein is suggested to be an inhibitor of [[alpha-synuclein]] aggregation, which occurs in [[neurodegenerative disease]]s such as [[Parkinson's disease]]. Thus, beta-synuclein may protect the [[central nervous system]] from the [[neurotoxicity|neurotoxic]] effects of alpha-synuclein and provide a novel treatment of neurodegenerative disorders.<ref>{{cite journal | last1 = Hashimoto | first1 = M | last2 = Bar-On | first2 = P | last3 = Ho | first3 = G | last4 = Takenouchi | first4 = T | last5 = Rockenstein | first5 = E | last6 = Crews | first6 = L | last7 = Masliah | first7 = E | title = Beta-synuclein regulates Akt activity in neuronal cells. A possible mechanism for neuroprotection in Parkinson's disease | journal = The Journal of Biological Chemistry | volume = 279 | issue = 22 | pages = 23622–9 | year = 2004 | pmid = 15026413 | doi = 10.1074/jbc.M313784200 }}</ref><ref>{{cite journal | last1 = Hashimoto | first1 = M | last2 = Rockenstein | first2 = E | last3 = Mante | first3 = M | last4 = Mallory | first4 = M | last5 = Masliah | first5 = E | title = beta-Synuclein inhibits alpha-synuclein aggregation: a possible role as an anti-parkinsonian factor | journal = Neuron | volume = 32 | issue = 2 | pages = 213–23 | year = 2001 | pmid = 11683992 | doi=10.1016/S0896-6273(01)00462-7}}</ref> | ||
==See also== | ==See also== | ||
Line 62: | Line 16: | ||
==References== | ==References== | ||
{{reflist | {{reflist}} | ||
==Further reading== | ==Further reading== | ||
{{refbegin | 2}} | {{refbegin | 2}} | ||
{{PBB_Further_reading | {{PBB_Further_reading | ||
| citations = | | citations = | ||
*{{cite journal | | *{{cite journal | vauthors=Jakes R, Spillantini MG, Goedert M |title=Identification of two distinct synucleins from human brain |journal=FEBS Lett. |volume=345 |issue= 1 |pages= 27–32 |year= 1994 |pmid= 8194594 |doi=10.1016/0014-5793(94)00395-5 }} | ||
*{{cite journal | | *{{cite journal | vauthors=Jensen PH, Hojrup P, Hager H |title=Binding of Abeta to alpha- and beta-synucleins: identification of segments in alpha-synuclein/NAC precursor that bind Abeta and NAC |journal=Biochem. J. |volume=323 |issue= Pt 2|pages= 539–46 |year= 1997 |pmid= 9163350 |doi= | pmc=1218353 |display-authors=etal}} | ||
*{{cite journal | | *{{cite journal | vauthors=Pronin AN, Morris AJ, Surguchov A, Benovic JL |title=Synucleins are a novel class of substrates for G protein-coupled receptor kinases |journal=J. Biol. Chem. |volume=275 |issue= 34 |pages= 26515–22 |year= 2000 |pmid= 10852916 |doi= 10.1074/jbc.M003542200 }} | ||
*{{cite journal | | *{{cite journal | vauthors=Rockenstein E, Hansen LA, Mallory M |title=Altered expression of the synuclein family mRNA in Lewy body and Alzheimer's disease |journal=Brain Res. |volume=914 |issue= 1–2 |pages= 48–56 |year= 2001 |pmid= 11578596 |doi=10.1016/S0006-8993(01)02772-X |display-authors=etal}} | ||
*{{cite journal | | *{{cite journal | vauthors=Tanji K, Mori F, Nakajo S |title=Expression of beta-synuclein in normal human astrocytes |journal=NeuroReport |volume=12 |issue= 13 |pages= 2845–8 |year= 2001 |pmid= 11588588 |doi=10.1097/00001756-200109170-00018 |display-authors=etal}} | ||
*{{cite journal | | *{{cite journal | vauthors=Hashimoto M, Rockenstein E, Mante M |title=beta-Synuclein inhibits alpha-synuclein aggregation: a possible role as an anti-parkinsonian factor |journal=Neuron |volume=32 |issue= 2 |pages= 213–23 |year= 2001 |pmid= 11683992 |doi=10.1016/S0896-6273(01)00462-7 |display-authors=etal}} | ||
*{{cite journal | | *{{cite journal | vauthors=Uversky VN, Li J, Souillac P |title=Biophysical properties of the synucleins and their propensities to fibrillate: inhibition of alpha-synuclein assembly by beta- and gamma-synucleins |journal=J. Biol. Chem. |volume=277 |issue= 14 |pages= 11970–8 |year= 2002 |pmid= 11812782 |doi= 10.1074/jbc.M109541200 |display-authors=etal}} | ||
*{{cite journal | | *{{cite journal | vauthors=Strausberg RL, Feingold EA, Grouse LH |title=Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences |journal=Proc. Natl. Acad. Sci. U.S.A. |volume=99 |issue= 26 |pages= 16899–903 |year= 2003 |pmid= 12477932 |doi= 10.1073/pnas.242603899 | pmc=139241 |display-authors=etal}} | ||
*{{cite journal | | *{{cite journal | vauthors=Ihara M, Tomimoto H, Kitayama H |title=Association of the cytoskeletal GTP-binding protein Sept4/H5 with cytoplasmic inclusions found in Parkinson's disease and other synucleinopathies |journal=J. Biol. Chem. |volume=278 |issue= 26 |pages= 24095–102 |year= 2003 |pmid= 12695511 |doi= 10.1074/jbc.M301352200 |display-authors=etal}} | ||
*{{cite journal | | *{{cite journal | vauthors=Fung KM, Rorke LB, Giasson B |title=Expression of alpha-, beta-, and gamma-synuclein in glial tumors and medulloblastomas |journal=Acta Neuropathol. |volume=106 |issue= 2 |pages= 167–75 |year= 2003 |pmid= 12783249 |doi= 10.1007/s00401-003-0718-x |display-authors=etal}} | ||
*{{cite journal | | *{{cite journal | vauthors=da Costa CA, Masliah E, Checler F |title=Beta-synuclein displays an antiapoptotic p53-dependent phenotype and protects neurons from 6-hydroxydopamine-induced caspase 3 activation: cross-talk with alpha-synuclein and implication for Parkinson's disease |journal=J. Biol. Chem. |volume=278 |issue= 39 |pages= 37330–5 |year= 2003 |pmid= 12867415 |doi= 10.1074/jbc.M306083200 }} | ||
*{{cite journal | | *{{cite journal | vauthors=Ohtake H, Limprasert P, Fan Y |title=β-Synuclein gene alterations in dementia with Lewy bodies |journal=Neurology |volume=63 |issue= 5 |pages= 805–11 |year= 2005 |pmid= 15365127 |doi= 10.1212/01.wnl.0000139870.14385.3c| pmc=1808539 |display-authors=etal}} | ||
*{{cite journal | | *{{cite journal | vauthors=Gerhard DS, Wagner L, Feingold EA |title=The Status, Quality, and Expansion of the NIH Full-Length cDNA Project: The Mammalian Gene Collection (MGC) |journal=Genome Res. |volume=14 |issue= 10B |pages= 2121–7 |year= 2004 |pmid= 15489334 |doi= 10.1101/gr.2596504 | pmc=528928 |display-authors=etal}} | ||
*{{cite journal | | *{{cite journal | vauthors=Snyder H, Mensah K, Hsu C |title=beta-Synuclein reduces proteasomal inhibition by alpha-synuclein but not gamma-synuclein |journal=J. Biol. Chem. |volume=280 |issue= 9 |pages= 7562–9 |year= 2005 |pmid= 15591046 |doi= 10.1074/jbc.M412887200 |display-authors=etal}} | ||
*{{cite journal | | *{{cite journal | vauthors=Sung YH, Eliezer D |title=Secondary structure and dynamics of micelle bound β- and γ-synuclein |journal=Protein Sci. |volume=15 |issue= 5 |pages= 1162–74 |year= 2006 |pmid= 16597821 |doi= 10.1110/ps.051803606 | pmc=2242515 }} | ||
*{{cite journal | | *{{cite journal | vauthors=Fan Y, Limprasert P, Murray IV |title=Beta-synuclein modulates alpha-synuclein neurotoxicity by reducing alpha-synuclein protein expression |journal=Hum. Mol. Genet. |volume=15 |issue= 20 |pages= 3002–11 |year= 2006 |pmid= 16959793 |doi= 10.1093/hmg/ddl242 |display-authors=etal}} | ||
*{{cite journal | | *{{cite journal | vauthors=Myslinski E, Gérard MA, Krol A, Carbon P |title=A genome scale location analysis of human Staf/ZNF143-binding sites suggests a widespread role for human Staf/ZNF143 in mammalian promoters |journal=J. Biol. Chem. |volume=281 |issue= 52 |pages= 39953–62 |year= 2007 |pmid= 17092945 |doi= 10.1074/jbc.M608507200 }} | ||
*{{cite journal | | *{{cite journal | vauthors=Sung YH, Eliezer D |title=Residual structure, backbone dynamics, and interactions within the synuclein family |journal=J. Mol. Biol. |volume=372 |issue= 3 |pages= 689–707 |year= 2007 |pmid= 17681534 |doi= 10.1016/j.jmb.2007.07.008 | pmc=2094134 }} | ||
}} | }} | ||
{{refend}} | {{refend}} | ||
{{protein-stub}} | ==External links== | ||
* {{UCSC gene info|SNCB}} | |||
<!-- The PBB_Controls template provides controls for Protein Box Bot, please see Template:PBB_Controls for details. --> | |||
{{PBB_Controls | |||
| update_page = yes | |||
| require_manual_inspection = no | |||
| update_protein_box = yes | |||
| update_summary = yes | |||
| update_citations = yes | |||
}} | |||
{{Nerve tissue protein}} | |||
{{gene-5-stub}} |
Latest revision as of 04:57, 30 August 2017
VALUE_ERROR (nil) | |||||||
---|---|---|---|---|---|---|---|
Identifiers | |||||||
Aliases | |||||||
External IDs | GeneCards: [1] | ||||||
Orthologs | |||||||
Species | Human | Mouse | |||||
Entrez |
|
| |||||
Ensembl |
|
| |||||
UniProt |
|
| |||||
RefSeq (mRNA) |
|
| |||||
RefSeq (protein) |
|
| |||||
Location (UCSC) | n/a | n/a | |||||
PubMed search | n/a | n/a | |||||
Wikidata | |||||||
|
Beta-synuclein is a protein that in humans is encoded by the SNCB gene.[1][2][3]
The protein encoded by this gene is highly homologous to alpha-synuclein. These proteins are abundantly expressed in the brain and putatively inhibit phospholipase D2 selectively. The encoded protein, which may play a role in neuronal plasticity, is abundant in neurofibrillary lesions of patients with Alzheimer's disease. This protein has been shown to be highly expressed in the substantia nigra of the brain, a region of neuronal degeneration in patients with Parkinson's disease; however, no direct relation to Parkinson's disease has been established. Two transcript variants encoding the same protein have been found for this gene.[3]
Beta-synuclein is a synuclein protein found primarily in brain tissue and is seen mainly in presynaptic terminals. Beta-synuclein is predominantly expressed in the neocortex, hippocampus, striatum, thalamus, and cerebellum. It is not found in Lewy bodies, but it is associated with hippocampal pathology in PD and DLB.[4]
Beta-synuclein is suggested to be an inhibitor of alpha-synuclein aggregation, which occurs in neurodegenerative diseases such as Parkinson's disease. Thus, beta-synuclein may protect the central nervous system from the neurotoxic effects of alpha-synuclein and provide a novel treatment of neurodegenerative disorders.[5][6]
See also
References
- ↑ Spillantini MG, Divane A, Goedert M (Nov 1995). "Assignment of human alpha-synuclein (SNCA) and beta-synuclein (SNCB) genes to chromosomes 4q21 and 5q35". Genomics. 27 (2): 379–81. doi:10.1006/geno.1995.1063. PMID 7558013.
- ↑ Lavedan C, Leroy E, Torres R, Dehejia A, Dutra A, Buchholtz S, Nussbaum RL, Polymeropoulos MH (Jan 1999). "Genomic organization and expression of the human beta-synuclein gene (SNCB)". Genomics. 54 (1): 173–5. doi:10.1006/geno.1998.5556. PMID 9806846.
- ↑ 3.0 3.1 "Entrez Gene: SNCB synuclein, beta".
- ↑ George, JM (2002). "The synucleins". Genome Biology. 3 (1): REVIEWS3002. doi:10.1186/gb-2001-3-1-reviews3002. PMC 150459. PMID 11806835.
- ↑ Hashimoto, M; Bar-On, P; Ho, G; Takenouchi, T; Rockenstein, E; Crews, L; Masliah, E (2004). "Beta-synuclein regulates Akt activity in neuronal cells. A possible mechanism for neuroprotection in Parkinson's disease". The Journal of Biological Chemistry. 279 (22): 23622–9. doi:10.1074/jbc.M313784200. PMID 15026413.
- ↑ Hashimoto, M; Rockenstein, E; Mante, M; Mallory, M; Masliah, E (2001). "beta-Synuclein inhibits alpha-synuclein aggregation: a possible role as an anti-parkinsonian factor". Neuron. 32 (2): 213–23. doi:10.1016/S0896-6273(01)00462-7. PMID 11683992.
Further reading
- Jakes R, Spillantini MG, Goedert M (1994). "Identification of two distinct synucleins from human brain". FEBS Lett. 345 (1): 27–32. doi:10.1016/0014-5793(94)00395-5. PMID 8194594.
- Jensen PH, Hojrup P, Hager H, et al. (1997). "Binding of Abeta to alpha- and beta-synucleins: identification of segments in alpha-synuclein/NAC precursor that bind Abeta and NAC". Biochem. J. 323 (Pt 2): 539–46. PMC 1218353. PMID 9163350.
- Pronin AN, Morris AJ, Surguchov A, Benovic JL (2000). "Synucleins are a novel class of substrates for G protein-coupled receptor kinases". J. Biol. Chem. 275 (34): 26515–22. doi:10.1074/jbc.M003542200. PMID 10852916.
- Rockenstein E, Hansen LA, Mallory M, et al. (2001). "Altered expression of the synuclein family mRNA in Lewy body and Alzheimer's disease". Brain Res. 914 (1–2): 48–56. doi:10.1016/S0006-8993(01)02772-X. PMID 11578596.
- Tanji K, Mori F, Nakajo S, et al. (2001). "Expression of beta-synuclein in normal human astrocytes". NeuroReport. 12 (13): 2845–8. doi:10.1097/00001756-200109170-00018. PMID 11588588.
- Hashimoto M, Rockenstein E, Mante M, et al. (2001). "beta-Synuclein inhibits alpha-synuclein aggregation: a possible role as an anti-parkinsonian factor". Neuron. 32 (2): 213–23. doi:10.1016/S0896-6273(01)00462-7. PMID 11683992.
- Uversky VN, Li J, Souillac P, et al. (2002). "Biophysical properties of the synucleins and their propensities to fibrillate: inhibition of alpha-synuclein assembly by beta- and gamma-synucleins". J. Biol. Chem. 277 (14): 11970–8. doi:10.1074/jbc.M109541200. PMID 11812782.
- Strausberg RL, Feingold EA, Grouse LH, et al. (2003). "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences". Proc. Natl. Acad. Sci. U.S.A. 99 (26): 16899–903. doi:10.1073/pnas.242603899. PMC 139241. PMID 12477932.
- Ihara M, Tomimoto H, Kitayama H, et al. (2003). "Association of the cytoskeletal GTP-binding protein Sept4/H5 with cytoplasmic inclusions found in Parkinson's disease and other synucleinopathies". J. Biol. Chem. 278 (26): 24095–102. doi:10.1074/jbc.M301352200. PMID 12695511.
- Fung KM, Rorke LB, Giasson B, et al. (2003). "Expression of alpha-, beta-, and gamma-synuclein in glial tumors and medulloblastomas". Acta Neuropathol. 106 (2): 167–75. doi:10.1007/s00401-003-0718-x. PMID 12783249.
- da Costa CA, Masliah E, Checler F (2003). "Beta-synuclein displays an antiapoptotic p53-dependent phenotype and protects neurons from 6-hydroxydopamine-induced caspase 3 activation: cross-talk with alpha-synuclein and implication for Parkinson's disease". J. Biol. Chem. 278 (39): 37330–5. doi:10.1074/jbc.M306083200. PMID 12867415.
- Ohtake H, Limprasert P, Fan Y, et al. (2005). "β-Synuclein gene alterations in dementia with Lewy bodies". Neurology. 63 (5): 805–11. doi:10.1212/01.wnl.0000139870.14385.3c. PMC 1808539. PMID 15365127.
- Gerhard DS, Wagner L, Feingold EA, et al. (2004). "The Status, Quality, and Expansion of the NIH Full-Length cDNA Project: The Mammalian Gene Collection (MGC)". Genome Res. 14 (10B): 2121–7. doi:10.1101/gr.2596504. PMC 528928. PMID 15489334.
- Snyder H, Mensah K, Hsu C, et al. (2005). "beta-Synuclein reduces proteasomal inhibition by alpha-synuclein but not gamma-synuclein". J. Biol. Chem. 280 (9): 7562–9. doi:10.1074/jbc.M412887200. PMID 15591046.
- Sung YH, Eliezer D (2006). "Secondary structure and dynamics of micelle bound β- and γ-synuclein". Protein Sci. 15 (5): 1162–74. doi:10.1110/ps.051803606. PMC 2242515. PMID 16597821.
- Fan Y, Limprasert P, Murray IV, et al. (2006). "Beta-synuclein modulates alpha-synuclein neurotoxicity by reducing alpha-synuclein protein expression". Hum. Mol. Genet. 15 (20): 3002–11. doi:10.1093/hmg/ddl242. PMID 16959793.
- Myslinski E, Gérard MA, Krol A, Carbon P (2007). "A genome scale location analysis of human Staf/ZNF143-binding sites suggests a widespread role for human Staf/ZNF143 in mammalian promoters". J. Biol. Chem. 281 (52): 39953–62. doi:10.1074/jbc.M608507200. PMID 17092945.
- Sung YH, Eliezer D (2007). "Residual structure, backbone dynamics, and interactions within the synuclein family". J. Mol. Biol. 372 (3): 689–707. doi:10.1016/j.jmb.2007.07.008. PMC 2094134. PMID 17681534.
External links
- Human SNCB genome location and SNCB gene details page in the UCSC Genome Browser.
This article on a gene on human chromosome 5 is a stub. You can help Wikipedia by expanding it. |